Teck Resources vs Vir Biotechnology Inc. Common Stock — how do they compare? Teck Resources trades at $63.23 (market cap $32.79B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Teck Resources is far larger — about 18.2× Vir Biotechnology Inc. Common Stock's market cap, and Teck Resources pays a 0.53% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teck Resources for 15 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TECK | VIR | |
|---|---|---|
Market Cap | $32.79B | $1.80B |
Volume | 1,600,168 | 1,782,836 |
Sector | Basic Materials | Health |
52-Week High | $71.97 | $11.78 |
52-Week Low | $38.23 | $5.12 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $35.41B | $1.36B |
Dividend Yield | 0.53% | — |
Signals from Pluang's Aura AI — not financial advice
TECK trades at $67.17, down 0.55% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue and net income are projected to grow significantly in 2026, supported by a 17.85% net margin. Analyst consensus is strongly bullish, with 69% buy ratings, amid positive news flow including inclusion in Forbes' top companies for women and copper price optimism.
Outlook remains positive given earnings momentum and copper demand tailwinds, but risks include commodity price volatility and execution of the Anglo American merger. Cash flow turned positive in 2026 forecasts, though 2025 saw a net outflow. The stock offers value with a P/E of 18.82 and EV/EBITDA of 7.77, but investors should monitor merger progress and global economic conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →